Healthpeak Properties (NYSE: DOC) and Brookfield Asset Management announced a $2.1 billion joint venture on July 20, 2026, covering 86 outpatient medical buildings totaling 5.6 million square feet across 11 states. Brookfield acquired a non-controlling 49% stake for roughly $1.03 billion, about $380 per square foot, while Healthpeak keeps 51%, management control, and the fee streams. This is the clearest private-market validation of outpatient medical values in years, and it carries three lessons worth more than the headline.
The Deal Structure
Healthpeak contributed the portfolio (95% leased, six-year weighted average lease term, spread across Kentucky, Indiana, Pennsylvania, Arkansas, Illinois, Minnesota, New Jersey, and New York) and remains managing member providing asset management, leasing, and property management. The implied valuation works out to roughly a 5.9% trailing cap rate. The distinctive term: after year seven, Healthpeak holds a call right to repurchase Brookfield’s stake at a price guaranteeing Brookfield a 6.5% annual return. Newmark advised.
Three Things This Deal Actually Tells You
First, the pricing is a public benchmark. A sophisticated buyer paid $380 per square foot at a high-5s cap for stabilized outpatient medical. Every medical office portfolio in our healthcare REIT rankings can now be marked against a real 2026 print, and it lands above where public-market pricing implied these assets traded, quiet support for the sector’s NAVs.
Second, the guaranteed-return structure is spreading. A 6.5% preferred return to institutional capital echoes the University of California’s 11.25% guaranteed deal with BREIT in 2023, which we detail on our BREIT review. Institutions increasingly negotiate floors that ordinary shareholders never receive. Here it cuts the other way: Healthpeak granted the floor to raise $1 billion without issuing equity below NAV, arguably shrewd capital allocation in a market where REIT shares trade at discounts.
Third, Brookfield keeps buying real estate through every side door. A Peakstone take-private in May (our PKST page tells that story), a $2.1 billion medical JV in July. When the world’s largest alternative managers consistently buy REIT assets at premiums to public pricing, the arbitrage they see is the discount the stock market applies to the same buildings.
What It Means for Healthpeak’s Grade
Healthpeak carries a B (72) in our rankings (full analysis on the Healthpeak DOC page). This transaction supports the grade rather than changing it: over $1 billion of proceeds at a premium valuation strengthens the balance sheet and funds buybacks or redeployment, while the retained management platform adds a fee-income stream the market rarely credits. The watch item is reinvestment: capital recycled from stabilized assets must land somewhere accretive, and that execution, not this announcement, will decide whether the grade moves.
Frequently Asked Questions
What did Brookfield pay for the Healthpeak stake?
Approximately $1.03 billion for 49% of the venture, valuing the 86-building portfolio at about $2.1 billion, or roughly $380 per square foot at an implied high-5% cap rate.
Does Healthpeak still control the properties?
Yes. Healthpeak holds 51%, serves as managing member, runs leasing and property management, and holds a call right after year seven to repurchase Brookfield’s stake at a 6.5% guaranteed annual return to Brookfield.
Is this good for healthcare REIT valuations?
It is supportive: a major private buyer validated outpatient medical pricing above what public REIT share prices implied, a data point in favor of sector NAVs.
Sources: company announcement of July 20, 2026 and trade press coverage. Independent research, not investment advice.